FORM 2
THE PATENTS ACT, 1970
(39 of 1970)
&
THE PATENTS RULES, 2003
COMPLETE SPECIFICATION (See section 10, rule 13)
“TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY
ANTAGONISTS”
ELI LILLY AND COMPANY, a corporation of the State of Indiana, United States of America of Lilly Corporate Center, Indianapolis, Indiana 46285, United States of America
The following specification particularly describes the invention and the manner in which it is to be performed.

TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS
The present invention relates to Hedgehog pathway antagonists and, more specifically, to novel tetrasubstituted pyridazines and therapeutic use thereof. The Hedgehog (Hh) signaling pathway plays an important role in embryonic pattern formation and adult tissue maintenance by directing cell differentiation and proliferation. The Hedgehog (Hh) protein family, which includes Sonic Hedgehog (Shh), Indian Hedgehog (Ihh), and Desert Hedgehog (Dhh) are secreted glycoproteins that undergo post-translational modifications, including autocatalytic cleavage and coupling of cholesterol to the amino-terminal peptide to form the fragment that possesses signaling activity. Hh binds to the twelve-pass transmembrane protein Ptch (Ptchl and Ptch2), thereby alleviating Ptch-mediated suppression of Smoothened (Smo). Smo activation triggers a series of intracellular events culminating in the stabilization of the Gli transcription factors (Gli 1, GH2, and GH3) and the expression of Gli-dependent genes that are responsible for cell proliferation, cell survival, angiogenesis and invasion.
Hh signaling has recently attracted considerable interest based on the discovery that aberrant activation of Shh signaling leads to the formation of various tumors, e.g., pancreatic cancer, medulloblastoma, basal cell carcinoma, small cell lung cancer, and prostate cancer. Several Hh antagonists have been reported in the art, such as the steroidal alkaloid compound IP-609; the aminoproline compound CUR61414; and the 2,4-disubstituted thiazole compound JK18. WO2005033288 discloses certain 1,4-disubstituted phthalazine compounds asserted to be hedgehog antagonists. Similarly, WO2008110611 discloses certain 1,4 disubstituted phthalazine compounds related to the diagnosis and treatment of pathologies related to the hedgehog pathway.
There still exists a need for potent hedgehog pathway inhibitors, particularly those having desirable pharmacodynamic, pharmacokinetic and toxicology profiles. The present invention provides novel tetrasubstituted pyridazines that are potent antagonists of this pathway.

The present invention provides a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein: X is C-R or N; R1 is hydrogen, fluoro or cyano;

or gem di-fluoro-substituted cyclohexyl;
R3 is methyl or trifluoromethyl;
R4 is pyrrolidinyl, morpholinyl or pyridyl, amino or dimethylamino;
R5 is trifluoromethyl, or methylsulfonyl;
R6 is hydrogen or methyl; and
R7, R8, R9, R10 and R11 are independently hydrogen fluoro, cyano, chloro, methyl, trifluoromethyl, trifluoromethoxy or methylsulfonyl, provided that al least two of R7, R8, R9, R10 and R11 are hydrogen.
It will be understood by the skilled artisan that the compounds of the present invention comprise a tertiary amine moiety and are capable of reaction with a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts. Such pharmaceutically acceptable acid addition salts and common methodology for preparing them are well known in the art. See, e.g., P. Stahl, et al, HANDBOOK OF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION AND USE, (VCHA/Wiley-VCH, 2002); S.M. Berge, et al, "Pharmaceutical Salts, " Journal of 'Pharmaceutical Sciences, Vol 66, No. 1, January 1977.
Specific embodiments of the invention include compounds of Formula I, or a pharmaceutically acceptable salt thereof, wherein:
(a) X is C-R1
(b) R1 is fluoro;

The present invention also provides a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable excipient, carrier or diluent.
The compounds of the present invention are preferably formulated as pharmaceutical compositions administered by a variety of routes. Preferably, such compositions are for oral or intravenous administration. Such pharmaceutical compositions and processes for preparing them are well known in the art. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (A. Gennaro, et al, eds., 19th ed., Mack Publishing Co., 1995).
The present invention also provides a method of treating brain cancer, basal cell carcinoma, esophagus cancer, gastric cancer, pancreatic cancer, biliary tract cancer, prostate cancer, breast cancer, small cell lung cancer, non-small cell lung cancer, B-cell lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, liver cancer, kidney cancer or melanoma in a patient comprising administering to a patient in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
It will be understood that the amount of the compound actually administered will be determined by a physician under the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms. Dosages per day normally fall within the range of about 0.1 to about 5 mg/kg of body weight. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed. Therefore, the above dosage range is not intended to limit the scope of the invention in any way. This invention also provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, for use as a medicament.
Additionally, this invention provides use of a compound of Formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer. In particular, the cancer is selected from the group consisting of brain cancer, basal cell carcinoma, esophagus cancer, gastric cancer, pancreatic cancer, biliary tract cancer, prostate cancer, breast cancer, small cell lung cancer, non-small cell lung cancer,

B-cell lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, liver cancer, kidney cancer and melanoma.
Furthermore, this invention provides a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as an active ingredient for treating brain cancer, basal cell carcinoma, esophagus cancer, gastric cancer, pancreatic cancer, biliary tract cancer, prostate cancer, breast cancer, small cell lung cancer, non-small cell lung cancer, B-cell lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, liver cancer, kidney cancer or melanoma.
The compounds of Formula I, or salts thereof, may be prepared by a variety of procedures known in the art, as well as those described in the Schemes, Preparations, and Examples below. The specific synthetic steps for each of the routes described may be combined in different ways, or in conjunction with steps from different schemes, to prepare compounds of Formula I, or salts thereof.
The substituents, unless otherwise indicated, are as previously defined. The reagents and starting materials are generally readily available to one of ordinary skill in the art. Others may be made by standard techniques of organic and heterocyclic chemistry, techniques which are analogous to the syntheses of known structurally-similar compounds, and the procedures described in the Preparations and Examples which follow including any novel procedures.
As used herein, the following terms have the meanings indicated: "boc" or "t-boc" refers to tert-butoxycarbonyl; "BOP" refers to benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate; "DMA" refers to N,N-dimethylacetamide; "DMF" refers to N,N-dimethylformamide; "DMSO" refers to methylsulfoxide; "EDO" refers to l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; "Et20" refers to diethyl ether; "EtOAc" refers to ethyl acetate; "iPrOH" refers to isopropanol; "MeOH" refers to methanol; "TFA" refers to trifluoroacetic acid; "SCX" refers to strong cation exchange; "PyBOP" refers to benzotriazol-1-yloxytripyrrolidino-phosphonium hexafluorophosphate; and "IC50" refers to the concentration of an agent that produces 50% of the maximal inhibitory response possible for that agent.
Scheme 1


A compound of Formula I can be prepared in accordance with reactions as depicted in Scheme 1.
In Scheme 1, Step 1, 3,6-dichloro-4,5-dimethylpyridazine (1) is displaced with tert-butyl methyl(piperidin-4-yl)carbamate (2) in a nucleophilic aromatic substitution reaction (SNAr) in a polar aprotic solvent such as DMF, DMA, or DMSO in the presence of an organic base such as triethylamine and/or diisopropylethylamine and/or an inorganic base such as potassium carbonate with heating to 100-140 °C to provide tert-butyl l-(6-chloro-4,5-dimethylpyridazin-3-yl)piperidin-4-yl(methyl)carbamate (3). In Step 2, the remaining chloride on the dimethylpyridazine can be reacted with an aryl boronic acid (4) in a Suzuki-Miyaura cross coupling reaction to give the corresponding 4,5-dimethyl-6-substituted arylpyridazine-3-substituted piperidine (5). The skilled artisan will recognize that there are a variety of conditions useful for facilitating such cross-coupling reactions. The reaction conditions make use of a suitable solvent such as dioxane or dioxane/water in the presence of a base such as cesium carbonate or cesium fluoride and a palladium catalyst such as (1,1'-
bis(diphenylphosphino)ferrocene)palladium(II) chloride or (SP-4-1)- bis[bis(l,l-dimethylethyl)(4-methoxyphenyl)phosphine-KP]dichloro-palladium (prepared according to J. Org. Chem. 2007, 72, 5104-5112) under an inert atmosphere at a temperature of about 80-160 °C to give a compound of formula (5). The amine can be deprotected by standard deprotection methods. Methods for introducing and removing nitrogen protecting groups are well known in the art (see, e.g., Greene and Wuts, Protective

Groups in Organic Synthesis, 3rd Ed., John Wiley and Sons, New York, (1999)). For example, boc deprotection of the amine of formula (5) can be accomplished under acidic conditions, such as hydrogen chloride or trifluoroacetic acid to give a compound of formula (6). Acylation of the amine in Step 4 can be accomplished with a substituted acid chloride (7) in an inert solvent such as dichloromethane or alternatively, a compound of formula (6) can be acylated using a substituted carboxylic acid and an appropriate coupling reagent such as PyBOP, pentafluorophenyl diphenylphosphinate, BOP, or EDCI and an appropriate base such as triethylamine or diisopropylethylamine in a suitable solvent such as DMF and/or DMSO, or dichloromethane to give neutral compounds of Formula I. Compounds of Formula I can be converted to a salt such as the HC1 salt by methods known to one skilled in the art such as adding HC1 in Et20 or the HCl can be generated in situ by dropwise addition of acetyl chloride to a solution of an alcohol solvent such as methanol at 0-20 °C.

The desired carboxylic acids (7), (Y = OH, Step 4, Scheme 1), can be prepared as shown in Scheme 2. The primary amine at the 2-position of the thiazole (8) is displaced with a chloride in a Sandmeyer reaction using copper chloride and isopentyl nitrite in an appropriate solvent such as acetonitrile as shown in Step 1 to give a 2-chloro-4,5-substituted thiazole (9). The chloride is then displaced with the desired amine (10) in Step 2 in a polar aprotic solvent such as DMSO to give the corresponding amino thiazole (11). Hydrolysis of the ester in Step 3 with a suitable base such as aqueous sodium hydroxide or aqueous lithium hydroxide in a suitable solvent such as MeOH or dioxane gives the desired carboxylic acid (12).
Scheme 3


In a further example of preparing the desired carboxylic acid (7), (Y = OH, Step 4, Scheme 1), as shown in Scheme 3, a pyrazole (13) is protected with a suitable protecting group such 4-methoxybenzyl as shown in Step 1 using an inorganic base such as potassium carbonate in a solvent such as acetone to give the protected pyrazole (14). The ester is then hydrolyzed with a suitable base as shown in Step 3 to give a compound of formula (15). Following acylation at Step 4, Scheme 1, deprotection of the pyrazole can be completed under acidic conditions such as TFA to give compounds of Formula 1.
Scheme 4 shows a still further example of preparing a carboxylic acid (7), (Y = OH, Step 4, Scheme 1).

Isopentyl nitrite can be added dropwise to a solution of an amino pyrazole (16) and dimethyl disulfide in an inert solvent such as chloroform to convert the primary amine to a thiomethyl group to form ethyl l-methyl-5-(methylthio)-lH-pyrazole-4-carboxylate (17) as shown in Step 1. The thiomethyl group of compound (17) can be oxidized to the methylsulfone with an oxidizing agent such as hydrogen peroxide in an appropriate solvent such as acetic acid to give a compound of formula 18, Step 2. Hydrolysis of the ester as previously described gives the appropriate carboxylic acid as shown in Step 3, compound (7).
The following Preparations and Examples are provided to illustrate the invention in further detail and represent typical syntheses of the compounds of Formula (I). The

names of the compounds of the present invention are generally provided by ChemDraw Ultra® 10.0.
Preparation 1 tert-Butyl l-(6-chloro-4,5-dimethylpyridazin-3-yl)piperidin-4-yl(methyl)carbamate

Heat a mixture of 3,6-dichloro-4,5-dimethylpyridazine (11.0 g, 62.1 mmol), tert-butyl methyl(piperidin-4-yl)carbamate (23.3 g, 109 mmol), and powdered K2CO3 (17.2 g, 124 mmol) in DMSO (310 mL) at 120 °C for 2 d. Cool the reaction mixture, dilute with H20, and filter off the solid. Rinse the solid with H20, and dry under vacuum at 45 °C. Dissolve the solid in CH2CI2, and pass the solution through a pad of silica gel, eluting with CH2CI2. Concentrate the organic layer under reduced pressure to obtain the title compound as a yellow solid (14.3 g, 65%). ES/MS m/z (35C1) 355.0 (M+l).
Preparation 2 tert-Butyl l-(6-(4-fluorophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-
yl(methyl)carbamate

Heat a mixture of tert-butyl l-(6-chloro-4,5-dimethylpyridazin-3-yl)piperidin-4-yl(metriyl)carbamate (1.5 g, 4.23 mmol), 4-fluorophenylboronic acid (887 mg, 6.34 mmol), Cs2C03 (5.51 g, 16.9 mmol) and (SP-4-l)-bis[bis(l,l-dimethylethyl)(4-methoxyphenyl)phosphine-KP]dichloro-palladium (/. Org. Chem. 2007, 72, 5104-5112) (29 mg, 0.042 mmol) in a mixture of 1,4-dioxane (30 mL) and H20 (10 mL) under N2 at 90 °C overnight. Partition the reaction mixture between H2O and CH2CI2. Separate the layers, and extract the aqueous layer with CH2CI2. Combine the organic layers, dry over Na2S04, filter, and concentrate under reduced pressure. Purify the residue by flash silica gel chromatography (gradient of 0 to 2% 2 M NH3/MeOH in CH2C12) to provide the title compound as a white foam (1.05 g, 60%). ES/MS m/z 415.2 (M+l).

Alternate procedure:
Treat aN2 degassed mixture of tert-butyl l-(6-chloro-4,5-dimethylpyridazin-3-yl)piperidin-4-yl(methyl)carbamate (3.01 g, 8.48 mmol), 4-fluorophenylboronic acid (1.23 g, 8.80 mmol) and CsF (4.08 g, 26.8 mmol) in 1,4-dioxane (80 mL) with (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) chloride (1.10 g, 1.35 mmol). Heat the resulting mixture under N2 at 95 °C overnight. Partition the reaction mixture between H2O and EtOAc. Separate the layers, and wash the organic layer with brine. Dry the organic layer over Na2S04, filter, and concentrate under reduced pressure. Purify the residue by flash silica gel chromatography (gradient of 20 to 80% EtOAc in hexanes) to provide the title compound (3.05 g, 87%). ES/MS m/z 415.2 (M+l).
Preparation 3
tert-Butyl 1 -(6-(4-cyanophenyl)-4,5-dimethylpyridazin-3 -yl)piperidin-4-
yl(methyl)carbamate

Heat a mixture of tert-butyl l-(6-chloro-4,5-dimethylpyridazin-3-yl)piperidin-4-yl(methyl)carbamate (1.5 g, 4.23 mmol), 4-cyanophenylboronic acid (932 mg, 6.34 mmol), CS2CO3 (5.51 g, 16.9 mmol) and (SP-4-l)-bis[bis(l,l-dimethylethyl)(4-methoxyphenyl)phosphine-KP]dichloro-palladium (29 mg, 0.042 mmol) in a mixture of 1,4-dioxane (30 mL) and H2O (10 mL) under N2 at 90 °C overnight. Partition the reaction mixture between EtOAc and H20 with dissolved NaHC03. Separate the layers, and extract the aqueous layer with EtOAc. Combine the organic layers, dry over Na2S04, filter, and concentrate under reduced pressure. Purify the residue by flash silica gel chromatography (gradient of 0 to 2%> 2 M NH3/MeOH in CH2C12) to provide the title compound as a yellow solid (1.68 g, 94%). ES/MS m/z 422.2 (M+l).
Prepare the substituted phenylpyridazines in the table below by essentially following the procedure described in Preparation 3, using the appropriately substituted

aryl boronic acid. For Preparation 5, directly filter the crude reaction mixture over a pad of silica gel eluting with 5% M NH3/MeOH in CH2CI2. Concentrate the eluent and purify without an aqueous work-up.

Preparation 6
l-(6-(4-Fluorophenyl)-4,5-dimethylpyridazin-3-yl)-N-methylpiperidin-4-amine

Treat a solution of tert-butyl l-(6-(4-nuorophenyl)-4,5-dimethylpyndazin-3-yl)piperidin-4-yl(methyl)carbamate (1.04 g, 2.51 mmol) in 1,4-dioxane (10 mL) with 4 M HC1 in 1,4-dioxane (15.0 mL). Stir the resulting mixture at ambient temperature for 2 h. Concentrate the reaction mixture under reduced pressure. Dissolve the residue in MeOH, and pour onto an SCX column (Varian, 10 g). Rinse the column with MeOH and CH2CI2, and elute the product with a 1:1 mixture of CH2CI2 and 2 M NH3/MeOH. Concentrate under reduced pressure to afford the title compound as an off-white solid (784 mg, 99%). ES/MSm/z 315.2 (M+l).
Preparation 7
4-(4,5-Dimethyl-6-(4-(methylamino)piperidin-1 -yl)pyridazin-3 -yl)benzonitrile


Treat a solution of tert-butyl l-(6-(4-cyanophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl(methyl)carbamate (1.68 g, 3.99 mmol) in 1,4-dioxane (20 mL) with 4 M HC1 in 1,4-dioxane (20 mL). Stir the resulting mixture at ambient temperature for 2 h. Concentrate the reaction mixture under reduced pressure. Dissolve the residue in MeOH, and pour onto an SCX column (Varian, 20 g). Rinse the column with MeOH and CH2CI2, and elute the product with a 1:1 mixture of CH2CI2 and 2 M NH3/MeOH. Concentrate under reduced pressure to afford the title compound as a yellow solid (1.28 g, quantitative). ES/MS m/z 322.2 (M+l).
Prepare the deprotected N-methylaminopiperidine in the table below by essentially following the procedure described in Preparation 7, using the appropriate boc-protected piperidine.N

Preparation 9
l-(4,5-Dimethyl-6-(pyridine-4-yl)pyridazin-3-yl)-N-methylpiperidin-4-amine
Add CH2C12 (20 mL) and trifluoroacetic acid (20 mL) to tert-butyl-l-(4,5-dimethyl-6-(pyridine-4-yl)pyridazin-3-yl)piperidin-4-yl(methyl)carbamate (1.19 g, 2.99 mmol). Stir at ambient temperature for 3 d. Concentrate under reduced pressure to give a residue. Partition the residue between CH2CI2 and 1 N NaOH. Separate the layers, and extract the aqueous layer twice with CH2CI2. Combine the organic extracts, dry over

Na2S04, filter, and concentrate under reduced pressure to obtain the title compound (790
mg, 89%). ES/MS m/z 298.2 (M+l).
Preparation 10
Ethyl 2-chloro-4-(trifluoromethyl)thiazole-5-carboxylate

Slowly treat a 0 °C mixture ofCuCl2 (671 mg, 4.99 mmol) and isopentyl nitrite (732 mg, 6.24 mmol) in acetonitrile (10 mL) with ethyl 2-amino-4-(trifluoromethyl)thiazole-5-carboxylate (1.0 g, 4.16 mmol). Stir the resulting mixture at ambient temperature for 1 h. Heat to 50 °C for 1 h. Remove most of the solvents, and pour into a mixture of ice and concentrated HC1. Extract with CH2CI2. Wash the organic layer with brine, dry over Na2S04, filter, and concentrate under reduced pressure. Purify the resulting residue by flash silica gel chromatography (20:1 hexanes: EtOAc) to give the title compound (762 mg, 71%). XH NMR (300 MHz, DMSO-d6) 8 1.26 (t, J = 7.0 Hz, 3H),4.31 (q, J = 7.0 Hz, 2H).
Preparation 11
Ethyl 2-morpholino-4-(trifluoromethyl)thiazole-5-carboxylate

Add ethyl 2-chloro-4-(trifluoromethyl)thiazole-5-carboxylate (4.00 g, 15.4 mmol) to a solution of morpholine (4.03 g, 46.2 mmol) in DMSO (10 mL). Stir the reaction at ambient temperature overnight. Add CH2CI2, and wash the mixture with H2O. Dry the organic phase over Na2S04, filter, and concentrate under reduced pressure. Purify the resulting residue by flash silica gel chromatography (20:5:1 hexanes: EtOAc: 2 M NH3/MeOH) to yield the title compound (4.58 g, 96%). ES/MS m/z 311.0 (M+l).

Prepare the amino thiazole esters in the table below by essentially following the procedure as described in Preparation 11, using the appropriate amine.

Preparation 15
2-Morpholino-4-(trifluoromethyl)thiazole-5-carboxylic acid

Add ethyl 2-morpholino-4-(trifluoromethyl)thiazole-5-carboxylate (4.58 g, 14.8 mmol) to a mixture of 1 N NaOH (20 mL) in MeOH (20 mL), and heat the reaction to 50 °C for 1 h. Concentrate the reaction under reduced pressure, and add H20 to the residue. Acidify the mixture to pH 4, and filter the solid. Wash the solid with H2O, and dry to obtain the title compound (4.13 g, 99%). ES/MS m/z 283.0 (M+l).
Prepare the amino thiazole acids in the table below by essentially following the procedure as described in Preparation 15, using the appropriate ester.


Preparation 19
(5)-tert-Butyl 2-(( 1 -(6-(4-fluorophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)(methyl)carbamoyl)piperidine-1 -carboxylate

Sequentially treat a solution of l-(6-(4-fluorophenyl)-4,5-dimethylpyridazin-3-yl)-JV-methylpiperidin-4-amine (100 mg, 0.318 mmol) in CH2C12 (3.2 mL) with (S)-l-(tert-butoxycarbonyl)piperidine-2-carboxylic acid (109 mg, 0.477 mmol), triethylamine (0.067 mL, 0.477 mmol) and EDCI (92 mg, 0.477 mmol). Stir the resulting mixture at ambient temperature for 2 d. Pour the reaction mixture into H20 containing NaHC03. Separate the layers, and extract the aqueous layer with CH2CI2. Combine the organic layers, dry over Na2S04, filter, and concentrate under reduced pressure. Purify the residue by flash

silica gel chromatography (gradient of 0 to 2% 2 M NH3/MeOH in CH2C12) to afford the title compound as a white solid (82 mg, 49%). ES/MS m/z 526.2 (M+l).
Preparation 20
Ethyl 1 -(4-methoxybenzyl)-3 -(trifluoromethyl)- lH-pyrazole-4-carboxylate

Add K2CO3 (503 mg, 3.60 mmol) to a solution of ethyl 3-(trifluoromethyl)-\H-pyrazole-4-carboxylate (500 mg, 2.40 mmol) in acetone (8 mL) at ambient temperature under N2. Add 1-bromomethyl-4-methoxybenzene (0.51 mL, 3.6 mmol) dropwise to the mixture, and stir overnight under N2. Quench the reaction with H2O, and extract twice with EtOAc. Dry the combined organic layers over MgS04, filter, and concentrate under reduced pressure. Purify the residue by flash silica gel chromatography (gradient of 0 to 15% EtOAc in hexanes) to yield the title compound (789 mg, quantitative). ES/MS m/z 351.0 (M+Na).
Preparation 21
l-(4-Methoxybenzyl)-3-(trifluoromethyl)-lH-pyrazole-4-carboxylic acid

Add a solution of LiOH (122 mg, 5.03 mmol) in H2O (3 mL) to a stirred solution of ethyl l-(4-methoxybenzyl)-3 -(trifluoromethyl)- lH-pyrazole-4-carboxylate (550 mg, 1.68 mmol) in 1,4-dioxane (10 mL). Stir overnight at ambient temperature. Acidify to pH 5 with 1 N HC1 and extract with CH2C12 and 2X with 20% iPrOH in CHC13. Dry the combined organic layers with MgS04, filter and concentrate under reduced pressure to obtain 140 mg of the title compound as a white solid. Acidify the aqueous layer to pH 2-

3 with 1 N HC1, and extract twice with 20% iPrOH in CHCI3. Dry the combined organics over MgS04, filter, and add the solution to the initially obtained 140 mg white solids. Concentrate to afford the title compound as a white solid (426 mg, 85%). ES/MS m/z 299.0 (M-l).
Preparation 22 N-(l-(6-(4-Fluorophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-l-(4-methoxybenzyl)-N-methyl-3-(trifluoromethyl)-lH-pyrazole-4-carboxamide

Add PyBOP (343 mg, 0.65 mmol) and triethylamine (0.21 mL, 1.50 mmol) to a stirred solution of l-(6-(4-fluorophenyl)-4,5-dimethylpyridazin-3-yl)-N-methylpiperidin-4-amine (157 mg, 0.50 mmol) and l-(4-methoxybenzyl)-3-(trifluoromethyl)-lH-pyrazole-4-carboxylic acid (165 mg, 0.55 mmol) in anhydrous DMF (2.5 mL). Stir the resulting mixture at ambient temperature under N2 overnight. Concentrate, add MeOH, filter solids, and concentrate the filtrate. Dilute the residue with MeOH, and pour onto an SCX column (Thermo Scientific, 10 g). Wash with MeOH, and then elute the product with 2 M NH3/MeOH. Concentrate and purify by flash silica gel chromatography using a gradient of 0 to 10% (10 % 2 M NH3/MeOH in EtOAc) in hexanes to obtain the title compound as a white solid (170 mg, 43%). ES/MS m/z 597.0 (M+l).
Preparation 23
Ethyl 1 -methyl-5-(methylthio)- lH-pyrazole-4-carboxylate

Add isopentyl nitrite (0.5 mL, 3.75 mmol) to a stirred 5 °C solution of ethyl 1-methyl-5-amino-lH-pyrazole-4-carboxylate (1.69 g, 10.0 mmol) and dimethyl disulfide (1.79 mL, 20.0 mmol) in CHCI3 under nitrogen in a 3-necked flask equipped with a thermometer and a condenser. Allow the reaction to warm to 20 °C in a H2O bath, and

treat with additional isopentyl nitrite (1.5 mL, 11.3 mmol) dropwise. After 15 min, remove the reaction from the 20 °C H2O bath (exotherm raises temperature to 50 °C over approximately 1 min). Stir at ambient temperature under N2 overnight. Wash with H2O, and separate the layers. Extract the aqueous layer with CHCI3, combine the organic layers, dry over MgS04, filter, and concentrate under reduced pressure. Purify the residue by flash silica gel chromatography (gradient of 0 to 35% EtOAc in hexanes) to afford the title compound (1.94 g, 97%). ES/MS m/z 201.0 (M+l).
Preparation 24
Ethyl 1 -methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxylate

Combine ethyl l-methyl-5-(methylthio)-1H-pyrazole-4-carboxylate (1.68 g, 8.39 mmol), glacial acetic acid (11 mL), and hydrogen peroxide (5.10 mL, 50.3 mmol) and heat the resulting mixture at 100 °C for 1.5 h. Allow the reaction to cool to ambient temperature and stir overnight. Add ice and extract twice with CH2CI2. Combine the organic layers, dry over MgSO4, filter, and concentrate under reduced pressure. Purify the residue by flash silica gel chromatography (gradient of 0 to 50% EtOAc in hexanes) to provide the title compound (1.95 g, 100%). ES/MS m/z 233.0 (M+l).
Preparation 25 1 -Methyl-5-(methylsulfonyl)- lH-pyrazole-4-carboxylic acid

Add a solution of LiOH (22 mg, 0.90 mmol) in H2O (1 mL) to a rapidly stirring solution of ethyl l-methyl-5-(methylsulfonyl)-17f-pyrazole-4-carboxylate (175 mg, 0.75 mmol) in 1,4-dioxane (3 mL) at ambient temperature. Treat the reaction mixture with additional LiOH (5 mg, 0.21 mmol), and stir overnight. Acidify to pH 2 with 1 N HC1,

and extract twice with CH2CI2. Combine the organic layers, dry over MgSO4, filter, and concentrate under reduced pressure to yield the title compound as a white solid (98 mg, 64%). ES/MS m/z 202.9 (M-l).
Example 1
4-Cyano-N-(l-(6-(4-cyanophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-N-
methylbenzamide hydrochloride

Treat a solution of 4-(4,5-dimethyl-6-(4-(methylamino)piperidin-l-yl)pyridazin-3-yl)benzonitrile (90 mg, 0.28 mmol) and triethylamine (0.12 mL, 0.84 mmol) in CH2CI2 (2.8 mL) with 4-cyanobenzoyl chloride (56 mg, 0.34 mmol). Stir the reaction at ambient temperature overnight. Wash with H2O and separate the layers. Directly purify the organic layer by flash silica gel chromatography (gradient of 0 to 2% 2 M NHs/MeOH in CH2CI2). Concentrate to afford a white solid. Dissolve the material in MeOH and add 1.1 eq of methanolic HC1 (preform by dripping acetyl chloride into MeOH). Concentrate the mixture under a stream of N2 gas and dry the residue in a vacuum oven at 45 °C to obtain the title compound as yellow solid (130 mg, 95%). ES/MS m/z 451.2 (M+l).
Prepare the piperadinylamides in the table below by essentially following the procedure described in Example 1, using the appropriate acid chloride with reaction times ranging from 6 h to 3 d. For Examples 7, 8 and 13, use excess 1 M HC1 in Et20 to form the salts. For Example 10, use 3 equivalents of preformed methanolic HC1 to form the salt.

Ex.
No. Chemical Name Structure ES/MS m/z

Example 14
A^-(l-(6-(4-Cyanophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-A^-methyl-2-(trifluoromethyl)nicotinamide dihydrochloride


Combine 4-(4,5-dimethyl-6-(4-(methylamino)piperidin-l-yl)pyridazin-3-yl)benzonitrile (102 mg, 0.32 mmol), 2-(trifluoromethyl)nicotinic acid (70 mg, 0.38 mmol), and triethylamine (0.13 mL, 0.96 mmol) in DMF (10 mL). Add PyBOP (200 mg, 0.38 mmol) to the mixture and stir overnight at ambient temperature. Add CH2CI2 to the reaction mixture and wash with brine. Dry the organic phase over Na2S04, filter, and concentrate under reduced pressure. Purify the resulting residue by flash silica gel chromatography (20:5:1 hexanes: EtOAc: 2 M NH3/MeOH). Add excess 1 M HC1 in Et20 to a solution of the free base in CH2Cl2/MeOH, and evaporate the solvents under N2 gas to yield the title compound (103 mg, 57%). ES/MS m/z 495.2 (M+l). Alternate coupling procedure:
Combine 4-(4,5-dimethyl-6-(4-(methylamino)piperidin-l-yl)pyridazin-3-yl)benzonitrile (300 mg, 0.93 mmol), 2-(trifluoromethyl)nicotinic acid (210 mg, 1.12 mmol) and diisopropylethylamine (0.79 mL, 4.51 mmol) in a 4:1 mixture of DMF and DMSO (20 mL). Heat the mixture briefly at 60 °C to dissolve the solids, and then cool to 0 °C. Add a solution of perfluorophenyl diphenylphosphinate (750 mg, 1.96 mmol) in a 4:1 mixture of DMF and DMSO (1 mL) dropwise. Heat the resulting mixture at 60 °C overnight. Partition the reaction mixture between aqueous NaHC03 solution and CH2CI2. Wash the organic layer with brine, dry over Na2S04, filter, and concentrate under reduced pressure. Purify the resulting residue by flash silica gel chromatography (20:5:1 hexanes: EtOAc: 2 M NH3/MeOH) to provide the free base of the title compound (346 mg, 75%). ES/MS m/z 495.2 (M+l). Form the HC1 salt as described above.
Prepare the piperidinyl amides in the table below by essentially following the procedure described in the first procedure for Example 14, using the appropriate dimethyl pyridazine and carboxylic acid. For Example 28, use 1.1 equivalents of 1 M HC1 in MeOH (preform by dripping acetyl chloride into MeOH) then concentrate to provide the monohydrochloride salt. For Example 28, follow the alternate procedure of Example 14.

Ex.
No. Chemical Name Structure ES/MS m/z

Example 29
N-(l-(6-(4-Cyanophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-N-methyl-4-(trifluoromethyl)nicotinamide hydrochloride

Treat a solution of 4-(4,5-dimethyl-6-(4-(methylamino)piperidin-l-yl)pyridazin-3-yl)benzonitrile (102 mg, 0.32 mmol), 4-(trifluoromethyl)nicotinic acid (81 mg, 0.42 mmol), triethylamine (0.07 mL, 0.5 mmol) in CH2C12 (4 mL) with EDCI (99 mg, 0.52 mmol) and stir for 3 d. Pour the reaction mixture into H20 and extract with EtOAc. Wash the organic layer with H20, dry over Na2S04, filter, and concentrate under reduced pressure. Purify by flash silica gel chromatography (gradient of 0 to 10% MeOH in CH2C12). Dissolve the free base in MeOH (2 mL) and add 1 M HC1 in Et20 (0.5 mL). Concentrate to provide the title compound (82 mg, 49%). ES/MS m/z 495.2 (M+l).
Prepare the piperidinyl amides in the table below by essentially following the procedure described in Example 29, using the appropriate carboxylic acid. For Examples

31-33, stir overnight. To form the HC1 salts in Examples 31-33, dissolve the corresponding free base in MeOH and add 1.1 equivalents of methanolic HC1 (preform by dripping acetyl chloride into MeOH) then concentrate.

Example 34
(S)-N-( 1 -(6-(4-Fluorophenyl)-4,5-dimethylpyridazin-3 -yl)piperidin-4-yl)-N-methylpiperidine-2-carboxamide dihydrochloride


Add 4 M HC1 in 1,4-dioxane (1.00 mL, 4.00 mmol) to a solution of (S)-tert-butyl 2-((l-(6-(4-fluorophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)(methyl)carbamoyl)piperidine-l-carboxylate (80 mg, 0.152 mmol) in CH2CI2 (2 mL). Stir the resulting mixture for 4 h at ambient temperature. Concentrate under reduced pressure and dry the residue in a vacuum oven at 45 °C to provide the title compound as pale yellow foam (79 mg, quantitative). ES/MS m/z 426.2 (M+l).
Example 35
N-(l-(6-(4-Fluorophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-N,l-dimethyl-5-(trifluoromethyl)- lH-pyrazole-4-carboxamide dihydrochloride

Dissolve l-(6-(4-fluorophenyl)-4,5-dimethylpyridazin-3-yl)-N-methylpiperidin-4-amine (800 mg, 4.12 mmol) in DMF (25 mL). Add l-methyl-5-(trifluoromethyl)-lH-pyrazole-4-carboxylic acid (1.08 g, 3.44 mmol), triethylamine (1.44 mL, 10.3 mmol) and PyBOP (2.68 g, 5.15 mmol). Stir at ambient temperature for 3 h. Concentrate the reaction mixture and purify the residue by flash silica gel chromatography using a gradient of 0-100% (5:1 EtOAc: 2 M NH3/MeOH) in hexanes. Dissolve the isolated product in CH2CI2 (10 mL) and add 2 M HC1 in Et20 (8 mL). Remove solvents under a stream of N2 and dry in a vacuum oven at 50 °C overnight to afford the title compound (612 mg, 32%). ES/MS (m/z) 491.2 (M+l).

Prepare the amides in the table below by essentially following the procedure described in Example 34, using the appropriate carboxylic acid. Purify Example 36 over an SCX column (eluting with 2 M NH3/MeOH) followed by flash chromatography.

Example 38
N-(l-(6-(4-Fluorophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-N-methyl-3-(trifluoromethyl)- lH-pyrazole-4-carboxamide dihydrochloride

Add trifluoroacetic acid (10 mL) to N-(l-(6-(4-fluorophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-l-(4-methoxybenzyl)-N-methyl-3-(trifluoromethyl)-17f-pyrazole-4-carboxamide (99 mg, 0.12 mmol) and heat at reflux under N2 overnight. Concentrate under reduced pressure. Dissolve the residue in 20% iPrOH in CHCI3, and wash with saturated aqueous Na2C03 solution. Extract the aqueous

layer with 20% iPrOH in CHCI3. Combine the organic layers, dry over MgSO4, filter, and concentrate under reduced pressure. Purify the residue by flash silica gel chromatography (gradient of 0 to 10% 2 M NH3/MeOH in CH2CI2). Dissolve the purified free base in CH2CI2 (2 mL) and add 1 M HC1 in Et20 (0.5 mL) dropwise. Stir for 30 min. Concentrate and dry in a vacuum oven at 50 °C overnight to provide the title compound (55 mg, 60%). ES/MS m/z 477.0 (M+l).
Biology
Hedgehog has been implicated as a survival factor for the following cancers: basal cell carcinoma; upper gastro intestinal tract cancers (esophagus, stomach, pancreas, and biliary tract); prostate cancer; breast cancer; small cell lung cancer; non-small cell lung cancer; B-cell lymphoma; multiple myeloma; gastric cancer; ovarian cancer; colorectal cancer; liver cancer; melanoma; kidney cancer; and brain cancer.
Elements of the hedgehog pathway have been asserted to be potential drug targets for the treatment of cancers. A Daoy cell line established from medulloblastoma tumor (ATCC, HTB-186), is responsive to Hh ligands. When these cells are treated with exogenously added Shh-conditioned media, Hh signaling pathway is activated and results in an increased expression of GUI. Cyclopamine, an alkaloid isolated from the corn lily Veratrum californicum is a weak hedgehog antagonist and has been shown to suppress the expression of GUI in response to Shh stimulation. Recent observations suggest that cyclopamine inhibits the growth of cultured medulloblastoma cells and allografts. Using this Daoy cell model system, potent inhibitors of hedgehog signaling pathways can be identified. Since the compounds of the present invention are hedgehog antagonists, they are suitable for treating the aforementioned tumor types.
Determination of Biological Activity IC50 The following assay protocol and results thereof further demonstrate the utility and efficacy of the compounds and methods of the current invention. Functional assays provide support that the compounds of the present invention exhibit the ability to inhibit Shh signaling. All ligands, solvents, and reagents employed in the following assay are

readily available from commercial sources or can be readily prepared by one skilled in the art.
Biological activity is determined using a functional assay in Daoy neuronal cancer cells and measures levels of GUI ribonucleic acid via a bDNA (branched deoxyribonucleic acid) assay system (Panomics, Inc., Fremont, CA). Gli was originally discovered in a Glioblastoma cell line and encodes a zinc finger protein that is activated by Shh signaling. The maximum response is obtained by inducing GUI transcription in the Daoy cells with conditioned medium (human embryonic kidney, HEK-293 cells stably expressing recombinant Shh) for 24 hours and then measuring the amount of stimulated GUI transcript. The minimum response is the amount of GUI transcript inhibited with a control compound in Daoy cells that have been stimulated with conditioned media (human embryonic kidney, HEK-293 cells stably expressing recombinant Shh) for 24 hours.
Functional Assay for Measuring the Inhibition of GUI in Daoy cells The bDNA assay system utilizes the technology of branched-chain DNA to allow amplification of a target ribonucleic acid (transcript). The technology employs three types of synthetic hybrid short G7z7-specific cDNA probes that determine the specificity of the target transcript [capture extenders (CEs), label extenders (LEs), and blockers (BLs)] that hybridize as a complex with the target transcripts to amplify the hybridization signal. The addition of a chemilumigenic substrate during the amplification step allows for detection using luminescence.
The Daoy cell line obtained from American Type Culture collection (ATCC) is a Shh-responsive human neuronal tumor cell line and was established in 1985 from a desmoplastic cerebellar medullablastoma tumor, a physiologically relevant tumor cell line. Endogenous levels of GUI transcripts levels are low in Daoy cells but can be stimulated by using conditioned media taken from cells stably over-expressing human Shh (a HEK-293 cell line stably transfected with hShh).
Daoy cells are grown to confluency in tissue culture T225-flasks in Daoy growth media containing Minimum Essential Medium (MEM) plus 10% Fetal Bovine Serum (FBS) with 0.1 nM non-essential amino acids and 1 mM sodium pyruvate. The cells are

removed from the T225-flasks using trypsin ethylenediaminetetraacetic acid (EDTA), centrifuged, resuspended in media, and then counted.
The Daoy cells are then seeded at 50,000 cells per well in growth media in Costar 96 well clear tissue culture plates and allowed to incubate overnight at 37 °C under 5% carbon dioxide (CO2). The cells are washed one time in phosphate buffered saline (PBS) followed by addition of 100 |xL of Shh Conditioned Media (Shh-CM) to stimulate levels of GUI expression. Shh-CM is diluted to achieve maximum stimulation using control growth media - 0.1% FBS/DMEM (Dulbeccos Modified Eagle Medium). Daoy cells treated with Shh-CM are then treated with various concentrations of hedgehog inhibitors ranging from approximately 1 |iM to 0.1 nM. Test compounds are allowed to incubate for 24 hours at 37 °C under 5% C02.
The measurement of the GUI transcript is performed by using the Quantigene 2.0 GUI assay as described by the manufacturer (Panomics, Inc.). Prepare a diluted lysis mixture (DLM) buffer, which includes Proteinase K. After a 24 hour incubation with compound, the cells are washed one time with PBS and 180 uL of DLM is added to the cells. The cell plate containing the lysis buffer is sealed and placed at 55 °C for 30 to 45 minutes. The resulting cell lysates are then triturated 5 times. A working probe set containing GUI probes is made by diluting the probes in the DLM according to the manufacturer's directions, and then 20 |xL of the working probe set is added to the bDNA assay plates along with 80 |xL of the Daoy lysates. The plates are sealed and incubated overnight at 55 °C. The bDNA plates are then processed according to the manufacturer's directions. The signal is quantified by reading the plates on a Perkin Elmer Envision reader detecting luminescence. The luminescent signal is directly proportional to the amount of target transcript present in the sample.
The luminescent signal data from the functional assay are used to calculate the IC50 for the in vitro assay. The data are calculated based on the maximum control values (Daoy cells treated with Shh-CM) and the minimum control value (Daoy cells treated with Shh-CM and an inhibitory concentration of a control compound, 1 |iM of N-(3-(lH-benzo[d]imidazol-2-yl)-4-chlorophenyl)-3,5-dimethoxybenzamide). A four parameter logistic curve fit is used to generate the IC50 values using ActivityBase software programs

version 5.3, equation 205 (Assay Guidance Manual Version 5.0, 2008, Eli Lilly and Company and NIH Chemical Genomics Center).
Following the protocol described, the compounds of the invention exemplified herein display an IC50 of < 15 nM. For example, the compound of Example 14 has an IC50 of approximately 1.27 nM with a standard error of 0.114 (n=4) and the compound of Example 34 has an IC50 of approximately 1.22 nM with a standard error 0.293 (n = 3) in the assay described above. These results provide evidence that the compounds of the present invention are hedgehog antagonists and, as such, are useful as anticancer agents.

We Claim:
1. A compound of the following formula:

or a pharmaceutically acceptable salt thereof, wherein: X is C-R1 or N; R1 is hydrogen, fluoro or cyano;

di-F-substituted cyclohexyl;
R3 is methyl or trifluoromethyl;
R4 is pyrrolidinyl, morpholinyl, pyridyl, amino or dimethylamino;
R5 is trifluoromethyl or methylsulfonyl;
R6 is hydrogen or methyl; and
R7, R8, R9, R10 and R11 are independently hydrogen fluoro, cyano, chloro, methyl, trifluoromethyl, trifluoromethoxy or methylsulfonyl, provided that at least two of R7, R8, R9, R10 and R11 are hydrogen.
2. The compound according to claim 1 wherein X is C-R1, or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 1 or 2 wherein R2 is:



or a pharmaceutically acceptable salt thereof.
4. The compound according to any one of claims 1-3 wherein R1 is hydrogen, fluoro or cyano, or a pharmaceutically acceptable salt thereof.
5. The compound according to any one of claims 1-4 wherein R1 is fluoro, or a pharmaceutically acceptable salt thereof.
6. The compound according to any one of claims 1-4 wherein R1 is cyano, or a pharmaceutically acceptable salt thereof.


7. The compound according to any one of claims 1-6 wherein R2 is

or a pharmaceutically acceptable salt thereof.


8. The compound according to any one of claims 1-7 wherein R2 is pharmaceutically acceptable salt thereof.

9. The compound according to any one of claims 1-7 wherein R2 is or a
pharmaceutically acceptable salt thereof.
10. The compound according to claim 8 wherein R5 is trifluoromethyl and R6 is methyl, or a pharmaceutically acceptable salt thereof.
11. The compound according to claim 9 wherein R7 is trifluoromethyl and R9, R10, and R11 are hydrogen, or a pharmaceutically acceptable salt thereof.
12. The compound according to any one of claims 1-4, 6, 7, 9, or 11 which is N-(1-(6-(4-cyanophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-N-methyl-2-(trifluoromethyl)nicotinamide, or a pharmaceutically acceptable salt thereof.
13. The compound according to claim 12 which is N-(1-(6-(4-cyanophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-N-methyl-2-(trifluoromethyl)nicotinamide dihydrochloride.
14. The compound according to any one of claims 1-4 which is N-(1-(6-(4-fluorophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-N-methyl-2-(trifluoromethyl)nicotinamide,
N-(1-(4,5-dimethyl-6-phenylpyridazin-3-yl)piperidin-4-yl)-N-methyl-2-(trifluoromethyl)nicotinamide,
N-(1-(6-(4-fluorophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-N-methyl-4-(trifluoromethyl)nicotinamide,
N-(1-(6-(4-cyanophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-N-methyl-4-(trifluoromethyl)nicotinamide,
N-(1-(4,5-dimethyl-6-phenylpyridazin-3-yl)piperidin-4-yl)-N-methyl-4-(trifluoromethyl)nicotinamide, or
N-(1-(6-(4-fluorophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-N,1-dimethyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide, or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 14 which is N-(1-(6-(4-fluorophenyl)-4,5-
dimethylpyridazin-3-yl)piperidin-4-yl)-N-methyl-2-(trifluoromethyl)nicotinamide
dihydrochloride,
N-(1-(4,5-dimethyl-6-phenylpyridazin-3-yl)piperidin-4-yl)-N-methyl-2-(trifluoromethyl)nicotinamide dihydrochloride,
N-(1-(6-(4-fluorophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-N-methyl-4-(trifluoromethyl)nicotinamide dihydrochloride,
N-(1-(6-(4-cyanophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-N-methyl-4-(trifluoromethyl)nicotinamide hydrochloride,
N-(1-(4,5-dimethyl-6-phenylpyridazin-3-yl)piperidin-4-yl)-N-methyl-4-(trifluoromethyl)nicotinamide hydrochloride, or
N-(1-(6-(4-fluorophenyl)-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)-N,1-dimethyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide dihydrochloride.
16. A pharmaceutical composition comprising a compound according to any one of claims 1-15, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, diluent or excipient.
17. A compound according to any one of claims 1-15, or a pharmaceutically acceptable salt thereof, for use as a medicament.
18. A compound according to any one of claims 1-15, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.
19. The compound or salt according to claim 18 wherein the cancer is selected from the group consisting of brain cancer, basal cell carcinoma, esophagus cancer, gastric cancer, pancreatic cancer, biliary tract cancer, prostate cancer, breast cancer, small-cell lung cancer, non-small cell lung cancer, B-cell lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, liver cancer, kidney cancer and melanoma.